What Are Psychobiotics? Human Evidence for Mood, Stress and Sleep

Quick Answer: What Are Psychobiotics, and Do They Work?

Psychobiotics are specific live microorganisms studied for possible effects on psychological outcomes through interactions with the gut-brain axis. The term originally referred to probiotics with potential mental-health effects, although modern research sometimes examines probiotics alongside prebiotics and synbiotics.

Human evidence is now broader than it was when the term was introduced. Recent systematic reviews and meta-analyses report average improvements in some depressive, anxiety, and stress-related outcomes, but results vary substantially by strain, formulation, population, study design, and outcome measure. The quality and consistency of the evidence also remain uneven.

The most important point is that psychobiotic evidence is not interchangeable. A result for one exact strain or tested combination cannot automatically be transferred to another strain, a species-level ingredient, or a finished supplement.

Psychobiotics are therefore best understood as an emerging adjunctive research area, not as established replacements for psychotherapy, medication, or professional mental-health care.

What Are Psychobiotics?

The term psychobiotic was introduced in 2013 to describe live microorganisms that might produce mental-health benefits when consumed in adequate amounts. Since then, the field has expanded substantially, but the central evidence question remains the same: does a defined microbial strain or formulation produce a measurable psychological outcome in humans?

That distinction separates psychobiotic research from the broader gut-brain axis. The gut and brain communicate through neural, immune, endocrine, and microbial-metabolite pathways, but demonstrating a plausible mechanism does not by itself establish that a bacterial strain improves mood, stress, anxiety, or another mental-health outcome.

This article therefore focuses on human outcome evidence, exact strain identity, tested combinations, and the difference between clinical findings and preclinical mechanisms.

How Strong Is the Human Evidence?

The human evidence for microbiome-targeted interventions and psychological outcomes has grown substantially, but more studies do not automatically mean more certainty.

A 2026 umbrella review brought together 30 systematic reviews and meta-analyses of randomized trials. Probiotic interventions showed an average benefit for depressive symptoms, while findings for anxiety were less consistent. Importantly, 76.6 percent of the included reviews were rated as having moderate, low, or critically low methodological quality, showing that the literature is larger but still uneven (Sá Filho et al., 2026, umbrella review).

A separate 2026 GRADE-assessed meta-analysis included 70 randomized controlled trials. It reported average reductions in depressive and anxiety symptoms, but there was substantial heterogeneity between studies in the strains or formulations used, populations studied, intervention duration, and psychological measures. The authors concluded that these interventions may have an adjunctive role but should not replace established treatments (Lian et al., 2026, meta-analysis).

The most useful conclusion is therefore not that psychobiotics work as a single category. It is that human evidence exists, but the strength and relevance of that evidence depend heavily on the exact intervention and the outcome being studied.

Bifidobacterium longum 1714: Human Evidence With Mixed Outcomes

Bifidobacterium longum 1714 has more direct human psychobiotic research than many individual strains, but its results illustrate why evidence should be interpreted outcome by outcome.

In a small 2016 study of healthy volunteers, B. longum 1714 was associated with lower daily perceived stress and an attenuated cortisol and anxiety response during an acute laboratory stressor, along with subtle cognitive changes (Allen et al., 2016, human study).

A larger 2026 randomized, double-blind, placebo-controlled trial tested B. longum 1714 for eight weeks in 168 adults with mild-to-moderate depression. The primary outcome, change in Beck Depression Inventory-II scores, was not significantly different from placebo at either four or eight weeks. Some secondary measures, including PHQ-9 scores, sleep quality, vitality, and selected mental-wellness measures, showed between-group differences, but the primary endpoint did not (Seamans et al., 2026, randomized controlled trial).

That makes 1714 a legitimate human-researched psychobiotic candidate, but not a proven antidepressant. The evidence is mixed, and the outcome being measured matters.

B. longum 1714 has also been studied for sleep-related outcomes. To keep this article focused on psychobiotics and mental wellness, detailed sleep evidence belongs in our Probiotics for Sleep guide.

Lactobacillus helveticus R0052 + Bifidobacterium longum R0175

A 2011 human study evaluated Lactobacillus helveticus R0052 together with Bifidobacterium longum R0175 and reported lower psychological distress during the intervention (Messaoudi et al., 2011, human study).

The important limitation is that the strains were tested as a combination. The finding therefore should not be presented as evidence that B. longum R0175 or L. helveticus R0052 produces the same effect when used alone, nor should it be transferred automatically to another formula containing either species.

Lactobacillus rhamnosus JB-1

Lactobacillus rhamnosus JB-1 is one of the most cited names in this field, and it is also the clearest lesson in reading the evidence carefully. In mice, JB-1 altered GABA receptor expression and reduced anxiety-like behavior, and those effects disappeared when the vagus nerve was cut, a striking demonstration of gut-brain communication (Bravo et al., 2011, animal study).

The nuance is essential. When the same strain was tested in a trial of healthy men, it produced no effect on stress, mood, sleep quality, the HPA stress response, inflammation, or cognition (Kelly et al., 2017, human study). The promising mouse findings did not translate. So JB-1 is a good example of why animal results are a starting point, not a conclusion, and why JB-1 evidence cannot be read across to a generic Lactobacillus rhamnosus ingredient.

Psychobiotic Evidence by Strain or Formulation

A quick guide to where the human evidence stands for the interventions with direct psychological outcome research, and what kind of evidence it is.

Bifidobacterium longum 35624: Why Strain Identity Matters

Older literature may refer to 35624 as Bifidobacterium infantis 35624. Genomic analysis later classified it as Bifidobacterium longum subsp. longum 35624 (Altmann et al., 2016, genomic study).

The strain is better established through gastrointestinal and immunoregulatory research than through direct human trials of mood or stress. It is therefore useful here mainly as an example of why both strain identity and current taxonomy matter when evaluating psychobiotic claims.

Evidence associated with 35624 should also not be transferred to a supplement merely because its label contains B. infantis or another B. longum strain.

Human Versus Preclinical Evidence: A Quick Hierarchy

Not all psychobiotic evidence answers the same question.

Meta-analyses and systematic reviews can estimate average effects across many studies, but high heterogeneity means they cannot identify one universally effective psychobiotic or prove that every probiotic has the same mental-health effect.

Randomized controlled trials of an exact strain or finished formulation provide the strongest evidence for strain-specific claims, especially when the study population and psychological outcome match the claim being made.

Small human trials in healthy volunteers can identify promising stress, mood, or cognitive signals, but they do not establish treatment effects in people with a diagnosed mental-health condition.

Animal studies can reveal mechanisms and generate hypotheses, but human trials may produce different results, as the JB-1 research illustrates.

Laboratory and mechanistic research can explain how a biological pathway might work without demonstrating a meaningful psychological benefit in people.

Two rules apply throughout: psychobiotic evidence is strain- and formulation-specific, and a finished multi-ingredient product has direct evidence only when that exact formulation has been tested.

What Meta-Analyses Can and Cannot Tell Us

Recent meta-analyses suggest that microbiome-targeted interventions can produce average improvements in some depression and anxiety symptom measures. However, those pooled estimates combine studies using different strains, multispecies formulas, doses, populations, intervention lengths, and psychological scales.

That variation matters. A statistically significant average effect across many studies does not show that every probiotic is a psychobiotic, identify one best strain for everyone, or establish that a particular commercial product will improve mood or anxiety.

Recent reviews also reach somewhat different conclusions depending on which trials and populations they include. A 2026 umbrella review found a more consistent signal for depressive symptoms than anxiety and identified substantial methodological weaknesses across the review literature, while another 2026 meta-analysis found average effects for both outcomes but substantial heterogeneity (Sá Filho et al., 2026; Lian et al., 2026).

The most defensible conclusion is that class-wide evidence supports continued clinical research, while individual recommendations still require exact strain, formulation, population, and outcome data.

Is Akkermansia muciniphila a Psychobiotic?

Akkermansia muciniphila is not currently established as a psychobiotic based on direct human mental-health evidence. Its better-supported human research concerns metabolic physiology and the intestinal environment, while research connecting Akkermansia specifically with mood, stress, anxiety, or depression remains much more limited.

That does not exclude future gut-brain relevance, but Akkermansia should not be grouped with strains that already have direct human psychobiotic outcome trials. For the Akkermansia-specific evidence related to depression and mood, see our dedicated Akkermansia and Depression review.

A Note on Mental Health Care

Psychobiotics are not a treatment for anxiety, depression, or insomnia, and nothing here is a substitute for professional care. If you are dealing with persistent low mood, anxiety, or sleep problems that affect your daily life, please talk with a qualified healthcare professional. Evidence-based treatments exist, and a probiotic, at best, is a possible complement to them for some people, not a replacement. If you ever feel unsafe or in crisis, contact local emergency services or a crisis line in your area.

A Personal Note

When I started working on the gut-brain axis, I expected a tidy set of pathways. What I found instead is a field that is genuinely hard, and genuinely interesting, precisely because the body does not read like a simple circuit. A strain that changes behavior in mice can do nothing measurable in people. A combination can outperform its parts. Small human trials point one way, and the next study complicates the picture. That is not a weakness of the science; it is what honest, early-stage research looks like.

Several individual strains and microbiome pathways discussed in this field have been investigated in human trials, while others remain supported primarily by preclinical research. Those studies should not be treated as trials of any finished Next-Microbiome product unless the exact formulation was tested. What keeps me interested is not a promise of quick fixes, but the slow, real progress of understanding how microbes and the nervous system talk to each other.

How to Evaluate a Psychobiotic Supplement

When a supplement is described as psychobiotic or as supporting the gut-brain axis, four questions are especially useful:

• What is the exact strain? Species names alone are not enough. Bifidobacterium longum 1714, for example, cannot be treated as interchangeable with every B. longum strain.

• Who was studied? Results in healthy volunteers do not automatically establish benefits for people with clinical depression, anxiety, or another diagnosed condition.

• What outcome was measured? Stress scores, depressive symptoms, anxiety scales, sleep quality, cortisol, and cognitive tests answer different questions.

• Was the finished formula tested? A multi-ingredient product does not inherit the clinical results of one ingredient unless the exact finished formulation itself was studied.

Some Next-Microbiome formulas contain species that also appear in gut-brain research. That is different from having direct psychobiotic evidence for the finished formula, and the distinction should remain clear when interpreting product claims.

The Bottom Line

Psychobiotics are a legitimate and growing field of human research, but the evidence remains uneven. Recent reviews suggest average benefits in some mood, depression, anxiety, and stress-related outcomes, while substantial differences between strains, formulations, populations, and study designs make broad conclusions difficult.

The strongest psychobiotic claims are therefore specific rather than general. A result for Bifidobacterium longum 1714 belongs to that strain. A result for Lactobacillus helveticus R0052 combined with B. longum R0175 belongs to that tested combination. And promising animal results, such as those involving L. rhamnosus JB-1, do not establish the same benefit in humans.

The practical question is not simply whether psychobiotics work. It is which exact strain or formulation was tested, in which population, for which outcome, and whether the observed effect was meaningful. Psychobiotics may have an adjunctive role in some settings, but they are not substitutes for established mental-health care.

Frequently Asked Questions About Psychobiotics

1. What are psychobiotics?

Psychobiotics are specific live microorganisms studied for possible effects on psychological outcomes through interactions with the gut-brain axis. Human research has examined outcomes such as perceived stress, depressive symptoms, anxiety, mood, cognition, and sleep, but results vary by exact strain and formulation.

2. Are psychobiotics the same as probiotics?

Not exactly. Probiotic is the broader category. The term psychobiotic is used when a probiotic or related microbiome-targeted intervention is specifically being studied for a psychological or gut-brain outcome. A probiotic should not be called an evidence-based psychobiotic simply because it belongs to the same species as a researched strain.

3. Which psychobiotics have human evidence?

Human research includes Bifidobacterium longum 1714 and the combination of Lactobacillus helveticus R0052 with B. longum R0175, among other interventions. The results are strain- and formulation-specific, and even well-studied strains can produce mixed outcomes across different trials.

4. Can psychobiotics support stress resilience?

Some specific strains have reduced perceived stress, cortisol responses, or psychological distress in human trials. However, these findings do not establish probiotics as treatments for chronic stress or anxiety disorders, and results should not be generalized beyond the tested strain or formulation.

5. Can psychobiotics help with depression or anxiety?

Recent meta-analyses report average improvements in some depressive and anxiety symptom measures, but the evidence is heterogeneous and study quality varies. Psychobiotics should therefore be considered an emerging adjunctive research area rather than a replacement for psychotherapy, medication, or other established care.

6. Is Lactobacillus rhamnosus JB-1 a proven psychobiotic?

Not in humans. JB-1 produced striking gut-brain effects in mice, but a randomized human study found no significant effects on stress, mood, sleep quality, HPA-axis response, inflammation, or cognition. It remains a useful example of why animal findings require human confirmation.

7. Can psychobiotics improve sleep?

Some specific probiotic strains and formulations have been studied for sleep outcomes, but sleep evidence is a separate research question from psychobiotic mood and stress evidence. For the human sleep studies and strain-specific results, see our Probiotics for Sleep guide.

8. How long do psychobiotics take to work?

There is no validated universal timeline. Trials use different strains, doses, populations, outcomes, and intervention lengths. A study duration should not be treated as a guaranteed personal response time.

9. Was Bifidobacterium infantis 35624 renamed?

Yes. Older publications often called the strain Bifidobacterium infantis 35624, but genomic analysis classified it as Bifidobacterium longum subsp. longum 35624. The change is another reason exact strain identification matters when reading probiotic research.

Related Reading

• For the biological pathways behind gut-brain communication, see our Microbiome Signaling guide.

• For research specifically connecting Akkermansia with depression and mood, see our Akkermansia and Depression review.

• For cortisol and the microbiome's relationship with stress signaling, see Cortisol and the Gut Microbiome.

• For SCFAs and HPA-axis research, see our SCFAs and Stress Recovery guide.

• For strain-specific sleep evidence, see our Probiotics for Sleep guide.

Scientific References

1. Dinan TG, Stanton C, Cryan JF.
   Psychobiotics: A Novel Class of Psychotropic
   Biological Psychiatry 2013;74(10):720-726 
   doi:10.1016/j.biopsych.2013.05.001 (Origin of the psychobiotic term)

2. Allen AP, Hutch W, Borre YE, et al.
   Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers
   Translational Psychiatry 2016;6(11):e939 
   doi:10.1038/tp.2016.191 (Human study, healthy volunteers)

3. Messaoudi M, Lalonde R, Violle N, et al.
   Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects 
   British Journal of Nutrition 2011;105(5):755-764 
   doi:10.1017/S0007114510004319 (Human study, combination formulation)

4. Bravo JA, Forsythe P, Chew MV, et al.
   Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve
   PNAS 2011;108(38):16050-16055
   doi:10.1073/pnas.1102999108 (Animal study, JB-1 mechanism)

5. Kelly JR, Allen AP, Temko A, et al.
   Lost in translation? The potential psychobiotic Lactobacillus rhamnosus (JB-1) fails to modulate stress or cognitive performance in healthy male subjects
   Brain, Behavior, and Immunity 2017;61:50-59
   doi:10.1016/j.bbi.2016.11.018 (Human study, JB-1 null translation)

6. Sá Filho AS, Souza TB, Martins JLR, et al.
   "Attacking" the Gut-Brain Axis with Psychobiotics: An Umbrella Review of Depressive and Anxiety Symptoms
   Pharmaceuticals (Basel) 2026;19(1):156 
   doi:10.3390/ph19010156 (Umbrella review of 30 systematic reviews and meta-analyses; methodological quality assessment)

7. Lian J, Yu W, Feng G, Miao D.
   Pre-/pro and synbiotics on anxiety and depression symptoms: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
   Annals of General Psychiatry 2026;25:45
   doi:10.1186/s12991-026-00661-6 (70 RCTs; pooled effects with substantial heterogeneity)

8. Seamans KM, Patterson E, Holz C, et al.
   Effects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial
   Experimental and Clinical Psychopharmacology 2026;34(4):341-351
   doi:10.1037/pha0000839 (168 adults with mild-to-moderate depression; primary BDI-II outcome not significantly different from placebo)

9. Altmann F, Kosma P, O'Callaghan A, et al.
   Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624
   PLoS One 2016;11(9):e0162983
   doi:10.1371/journal.pone.0162983 (Taxonomic reassignment of strain 35624)

Written by Ali Rıza Akın

Microbiome Scientist, Author & Founder of Next-Microbiome

Ali Rıza Akın is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation.

His work focuses on how microbial ecosystems interact with human physiology, including:

• Gut barrier function and intestinal permeability

• Mucus-associated microbiota (Akkermansia-related systems)

• Oral–gut microbiome axis

• Short-chain fatty acids (SCFAs) and metabolic signaling

• Circadian rhythm–microbiome interactions

• Clinical Research Contributions

He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including:

Active Ulcerative Colitis (Inflammatory Bowel Disease)

Hyperoxaluria (Oxalate Metabolism Disorder)

Microbiome-driven gut health and inflammatory conditions

These studies were part of broader clinical development programs evaluating microbiome-based approaches. His contributions focused on the early-stage scientific and translational pipeline, including strain discovery, functional optimization, and multi-strain formulation design.

Scientific Contributions:

Ali Rıza Akın is the discoverer of Christensenella californii, a bacterial species associated with microbiome diversity and metabolic health.

He is a contributing author to scientific publications and Bacterial Therapy of Cancer (Springer), and the author of Bakterin Kadar Yaşa: İçimizdeki Evren: Mikrobiyotamız.

Approach:

His work emphasizes evidence-based microbiome science, long-term safety, and a systems-based understanding of how microbes influence human health.

Review and Sources

This article is written and reviewed by a microbiome scientist and is based on peer-reviewed randomized trials, systematic reviews, meta-analyses, and preclinical studies listed in the Scientific References.

Human, animal, and mechanistic evidence are distinguished throughout, and exact strains or tested combinations are named where results are strain-specific. Recent evidence syntheses are used to describe class-wide findings without transferring those findings automatically to individual strains or finished products. The article is reviewed periodically against current psychobiotic, microbiome, and mental-health research.

Medical Disclaimer

This content is for educational and informational purposes only and is not medical advice. It does not diagnose, treat, cure, or prevent any disease or condition, including anxiety, depression, or insomnia. Psychobiotics and other dietary supplements are not substitutes for professional evaluation or evidence-based treatment. Speak with a qualified healthcare professional about persistent low mood, anxiety, or sleep problems, or before starting a new supplement if you are pregnant, nursing, managing a health condition, or taking medication.

Last reviewed and updated: September 2026